These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24830357)

  • 1. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study.
    Grothey A; Flick ED; Cohn AL; Bekaii-Saab TS; Bendell JC; Kozloff M; Roach N; Mun Y; Fish S; Hurwitz HI
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):726-34. PubMed ID: 24830357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
    Grothey A; Sugrue MM; Purdie DM; Dong W; Sargent D; Hedrick E; Kozloff M
    J Clin Oncol; 2008 Nov; 26(33):5326-34. PubMed ID: 18854571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study.
    Hurwitz HI; Bekaii-Saab TS; Bendell JC; Cohn AL; Kozloff M; Roach N; Mun Y; Fish S; Flick ED; Grothey A;
    Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):323-32. PubMed ID: 24686090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of bevacizumab exposure beyond disease progression in patients with non-small-cell lung cancer: analyses of the ARIES observational cohort study.
    Leon L; Kosty M; Jahanzeb M; Spigel D; Wozniak AJ; Brahmer J; Fish S; Flick ED; Hazard SJ; Lynch TJ
    Pharmacoepidemiol Drug Saf; 2016 May; 25(5):569-77. PubMed ID: 26748833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology.
    Cartwright TH; Yim YM; Yu E; Chung H; Halm M; Forsyth M
    Clin Colorectal Cancer; 2012 Dec; 11(4):238-46. PubMed ID: 22658457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study.
    Kabbinavar FF; Flynn PJ; Kozloff M; Ashby MA; Sing A; Barr CE; Grothey A
    Eur J Cancer; 2012 May; 48(8):1126-32. PubMed ID: 22424880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
    Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
    Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
    Budai B; Nagy T; Láng I; Hitre E
    Angiogenesis; 2013 Jan; 16(1):113-21. PubMed ID: 22956187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: the Gunma Clinical Oncology Group (GCOG) trial 001 SILK study.
    Tsutsumi S; Ishibashi K; Uchida N; Ojima H; Hosouchi Y; Yashuda N; Kigure W; Yamauchi S; Asao T; Ishida H; Kuwano H
    Oncology; 2012; 83(3):151-7. PubMed ID: 22889925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
    Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
    Bennouna J; Sastre J; Arnold D; Österlund P; Greil R; Van Cutsem E; von Moos R; Viéitez JM; Bouché O; Borg C; Steffens CC; Alonso-Orduña V; Schlichting C; Reyes-Rivera I; Bendahmane B; André T; Kubicka S;
    Lancet Oncol; 2013 Jan; 14(1):29-37. PubMed ID: 23168366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study.
    Kozloff MF; Berlin J; Flynn PJ; Kabbinavar F; Ashby M; Dong W; Sing AP; Grothey A
    Oncology; 2010; 78(5-6):329-39. PubMed ID: 20733336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
    Yang H; Yu AP; Wu EQ; Yim YM; Yu E
    J Med Econ; 2011; 14(5):542-52. PubMed ID: 21728912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
    Kochi M; Akiyama Y; Aoki T; Hagiwara K; Takahashi T; Hironaka K; Teranishi F; Osuka F; Takeuchi M; Fujii M; Nakajima T
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1097-102. PubMed ID: 24057041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged survival of patients with metastatic colorectal cancer following first-line oxaliplatin-based chemotherapy with molecular targeting agents and curative surgery.
    Shitara K; Matsuo K; Kondo C; Takahari D; Ura T; Inaba Y; Yamaura H; Sato Y; Kato M; Kanemitsu Y; Komori K; Ishiguro S; Sano T; Shimizu Y; Muro K
    Oncology; 2011; 81(3-4):167-74. PubMed ID: 22057124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
    Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
    Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma.
    Kiss I; Bortlicek Z; Melichar B; Poprach A; Halamkova J; Vyzula R; Dusek L; Buchler T
    Anticancer Res; 2014 Feb; 34(2):949-54. PubMed ID: 24511038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.
    Whyte S; Pandor A; Stevenson M; Rees A
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):47-53. PubMed ID: 21047491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of chemotherapy combined with bevacizumab for metastatic colorectal cancer].
    Momoi A; Motomura S; Hashimoto C; Takasaki H; Takemura S; Takagi S; Akaike M
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):79-83. PubMed ID: 21368462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.